Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial

After a review of clinical data from the Generation Program studies, Novartis, Amgen and Banner Alzheimer’s Institute have decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer’s Prevention Initiative Generation Program.

July 12th, 2019|News|

Study by MIT researchers could pave the way for new therapies for Alzheimers

Researchers performed the first comprehensive analysis of the genes altered in individual brain cells of patients with Alzheimer’s disease, allowing them to identify the distinctive cellular pathways affected in neurons and other types of brain cells.

May 1st, 2019|News|